Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (203)	5/31/2003 3:31:30 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 590

Erik, Data from only 40 pts, what is AMGN doing? Where are survival data (4, 6 and 12 months), TTP (especially for those 22 stable), and overall clinical activity and medical benefit? 10% + 55% may looks good if other data confirm translation of the drug clinical activity into medical benefit, relative to other options available for CC. However, (from TSC):"Amgen, which is largely in control of the drug's development for colon cancer, intends to conduct a phase III study once the phase II study is completed." If they wait until PII is completed, Erbitux will be on market for years! Miljenko PS: Their front line CC is ongoing, but AMGN is silent. Must be that IMCL patent is big bump on road.